Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Habermann

Showing results (81-90 of 374) with videos related to

Pageof 38
Sort By:
Mayo Clinic Proceedings|June 7, 2007
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximabThomas E Witzig, David J Inwards, Thomas M Habermann, et al.
The Oncologist|April 23, 2020
Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular LymphomaFrédérique St-Pierre, Stephen M Broski, Betsy R LaPlant, et al.
British Journal of Haematology|April 1, 2015
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)Lode J Swinnen, Hailun Li, Andrew Quon, et al.
British Journal of Haematology|August 26, 2010
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI)Ranjana H Advani, Haiyan Chen, Thomas M Habermann, et al.
Leukemia & Lymphoma|March 15, 2017
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issueAnthony Q Pham, Stephen M Broski, Thomas M Habermann, et al.
International Journal of Cardiology|October 16, 2018
Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomesJae Yoon Park, Wei Guo, Mohammed Al-Hijji, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2015
Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal WomenAlexis D Leal, Carrie A Thompson, Alice H Wang, et al.
International Journal of Cancer|October 12, 2013
Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohortAlexis D Leal, Carrie A Thompson, Alice H Wang, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 23, 2026
Immunity Gone Viral: Subacute Cognitive Decline With Multifocal Brain Lesions in Neuromyelitis Optica Spectrum DisorderSonali Ajwani, Brian G Weinshenker, Caterina Giannini, et al.
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
Pageof 38

Showing results (81-90 of 374) with videos related to

Sort By:
Pageof 38
Mayo Clinic Proceedings|June 7, 2007
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximabThomas E Witzig, David J Inwards, Thomas M Habermann, et al.
The Oncologist|April 23, 2020
Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular LymphomaFrédérique St-Pierre, Stephen M Broski, Betsy R LaPlant, et al.
British Journal of Haematology|April 1, 2015
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)Lode J Swinnen, Hailun Li, Andrew Quon, et al.
British Journal of Haematology|August 26, 2010
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI)Ranjana H Advani, Haiyan Chen, Thomas M Habermann, et al.
Leukemia & Lymphoma|March 15, 2017
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issueAnthony Q Pham, Stephen M Broski, Thomas M Habermann, et al.
International Journal of Cardiology|October 16, 2018
Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomesJae Yoon Park, Wei Guo, Mohammed Al-Hijji, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2015
Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal WomenAlexis D Leal, Carrie A Thompson, Alice H Wang, et al.
International Journal of Cancer|October 12, 2013
Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohortAlexis D Leal, Carrie A Thompson, Alice H Wang, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 23, 2026
Immunity Gone Viral: Subacute Cognitive Decline With Multifocal Brain Lesions in Neuromyelitis Optica Spectrum DisorderSonali Ajwani, Brian G Weinshenker, Caterina Giannini, et al.
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
Pageof 38